ATLANTA -- For transcatheter aortic valve replacement (TAVR) candidates with a small aortic annulus, the two leading platforms offered differing hemodynamic valve performances despite being similarly ...
Edwards Lifesciences' Sapien 3 transcatheter aortic valve has received FDA approval early. The FDA has approved the next-generation Sapien 3 transcatheter aortic valve (TAVR) from Edwards Lifesciences ...
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy ...
This collaboration aims to maximize the value of biobank data through AI-assisted harmonization, leading to precise patient outcomes at scale and lowering the cost of drug discovery. SAN FRANCISCO & ...
Off-label use of the Sapien and Sapien XT valves represents a “viable and durable option” for restoring pulmonary valve function in patients with right-ventricular outflow tract (RVOT) disorders, ...
IRVINE, CA, Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, today announced that it has received United States Food and Drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback